THE PLACE OF CORTICOTROPIN IN THE TREATMENT OF MYASTHENIA GRAVIS
Authors: L D FREYDBERG
Journal: Annals of Internal Medicine (1960)

Article1 April 1960THE PLACE OF CORTICOTROPIN IN THE TREATMENT OF MYASTHENIA GRAVISLEO D. FREYDBERG, M.D.LEO D. FREYDBERG, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-52-4-806 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptOpinion differs greatly on the value of corticotropin in treating myasthenia gravis. A review in 19551 shows reports in the literature of only 50 cases so treated, with 25 markedly improved. Despite this seemingly good average, there are few new reports. The large medical centers to which greater numbers of these patients gravitate have tried corticotropin on only a few.The use of corticotropin in myasthenia gravis was first considered when various investigators reported in 1943 that either corticotropin or adrenal cortex extracts would cause involution of the thymus and other lymphoid tissues.2, 3On the basis of these findings,...Bibliography1. Kane CA: The effect of certain endocrine glands on myasthenia gravis, Am. J. Med. 19: 729, 1955. CrossrefMedlineGoogle Scholar2. DoughertyWhite TFA: Effect of pituitary adrenotrophic hormone on lymphoid tissue, Proc. Soc. Exper. Biol. and Med. 53: 132, 1943. CrossrefGoogle Scholar3. SimpsonLiReinhardtEvans MECHWOHM: Similarity of response of thymus and lymph nodes to administration of adrenocorticotrophic hormone in the rat, Proc. Soc. Exper. Biol. and Med. 54: 135, 1943. CrossrefGoogle Scholar4. TordaWolff CHG: Effect of adrenotrophic hormone on ability of tissue to synthesize acetylcholine, Proc. Soc. Exper. Biol. and Med. 57: 137, 1944. CrossrefGoogle Scholar5. SofferGabriloveLaqueurVolterraJacobsSussman LJJLHPMMDML: The effects of anterior pituitary adrenocorticotrophic hormone (ACTH) in myasthenia gravis with tumor of the thymus, J. Mt. Sinai Hosp. 15: 73, 1948. MedlineGoogle Scholar6. TordaWolff CHG: Effects of adrenocorticotrophic hormone on neuromuscular function in patients with myasthenia gravis, J. Clin. Investigation 28: 1228, 1949. CrossrefMedlineGoogle Scholar7. TordaWolff CHG: Effects of administration of adrenocorticotrophic hormone (ACTH) on patients with myasthenia gravis, Arch. Neurol. and Psychiat. 66: 163, 1951. CrossrefMedlineGoogle Scholar8. Schlezinger NS: Present status of therapy in myasthenia gravis, J. A. M. A. 148: 508, 1952. CrossrefMedlineGoogle Scholar9. GrobHarvey DAM: Effect of adrenocorticotrophic hormone (ACTH) and cortisone administration in patients with myasthenia gravis and report of onset of myasthenia gravis during prolonged cortisone administration, Bull. Johns Hopkins Hosp. 91: 124, 1952. MedlineGoogle Scholar10. Osserman KE: Myasthenia gravis, 1958, Grune & Stratton, New York, pp. 15, 192. Google Scholar11. Randt CT: Myasthenia gravis, M. Clin. North America 37: 535, 1953. CrossrefMedlineGoogle Scholar12. Lamartine de Assis J: ACTH and cortisone in treatment of severe myasthenia gravis: 3 cases, Arq. neuro-psiquiat. (Sao Paulo, Brazil) 14: 28, 1956 (obtained from abstract in J. A. M. A. 161: 1007, 1956). MedlineGoogle Scholar13. ThevenardLegerMarques ALJM: Treatment of Erb-Goldflam myasthenia by denervation of carotid sinus, J. Internat. Coll. Surgeons 19: 548, 1953. MedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Troy, N. Y.*Received for publication September 2, 1959.Requests for reprints should be addressed to Leo D. Freydberg, M.D., 114 Second Street, Troy, N. Y. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byIntravenous immunoglobulins may prevent prednisone-exacerbation in myasthenia gravisHistory of outcome measures for myasthenia gravisChapter 1 The most vulnerable synapse: historic aspects of neuromuscular junction disordersClinical predictors of steroid-induced exacerbation in myasthenia gravisElectrophysiologic and Clinical Aspects of Glucocorticoids on Certain Neural SystemsALTERNATE-DAY PREDNISONE: PRELIMINARY REPORT OF A DOUBLE-BLIND CONTROLLED STUDY*Corticosteroides no tratamento da miastenia grave. Estudo de 12 casos com revisão da literaturaBenefit from adrenocorticotrophin in myasthenia gravisTreatment of ocular myasthenia with corticotrophinDie Pathogenese der Myasthenia gravis als immunologisches ProblemCorticotrofina e cortiomdes em neurologia: avaliação critica dos resultados em 518 pacientes hospitalizadosEndocrine Aspects of Myasthenia GravisTREATMENT OF SEVERE MYASTHENIA GRAVIS WITH LARGE DOSES OF ACTHMYASTHENIA AS AN AUTOIMMUNE DISEASE: CLINICAL ASPECTSRESULTS WITH ACTH AND SPIRONOLACTONE IN SEVERE CASES OF MYASTHENIA GRAVISDifferential Diagnosis of Muscle Weakness in Myasthenia Gravis, Polymyositis and Muscular DystrophyPharmacological Considerations in the Treatment of Myasthenia Gravis 1 April 1960Volume 52, Issue 4Page: 806-818KeywordsAdrenal cortexAdrenocorticotropic hormoneMyasthenia gravisParalysisThymus ePublished: 1 December 2008 Issue Published: 1 April 1960 PDF downloadLoading ...